ADMA Biologics (NASDAQ:ADMA) Given Daily News Sentiment Rating of 0.22
Media headlines about ADMA Biologics (NASDAQ:ADMA) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ADMA Biologics earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.925425973496 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- $6.81 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter (americanbankingnews.com)
- ADMA Biologics Inc (NASDAQ:ADMA) Releases Earnings Results, Misses Expectations By $0.29 EPS (americanbankingnews.com)
- ADMA Biologics Inc (ADMA) Expected to Post Earnings of -$0.42 Per Share (americanbankingnews.com)
- ADMA BIOLOGICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (4-traders.com)
- ADMA Biologics Provides Corporate Update and Reports Second Quarter 2017 Financial Results (finance.yahoo.com)
A number of research firms recently commented on ADMA. Maxim Group set a $13.00 price objective on shares of ADMA Biologics and gave the stock a “buy” rating in a research note on Monday, May 15th. ValuEngine lowered shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
ADMA Biologics (NASDAQ ADMA) traded up 0.68% during trading on Monday, reaching $2.96. 27,031 shares of the company were exchanged. The firm’s market cap is $38.14 million. ADMA Biologics has a 52-week low of $2.76 and a 52-week high of $7.70. The firm has a 50-day moving average of $3.47 and a 200-day moving average of $4.19.
ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Friday, August 11th. The biotechnology company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.29. The business had revenue of $3.40 million for the quarter, compared to analysts’ expectations of $3.52 million. On average, equities analysts forecast that ADMA Biologics will post ($1.28) EPS for the current year.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.